Make faster and more data-driven treatment decisions – reducing delays in identifying and acting on patients with abnormal brain medical images when time is critical
The Neuro AI platform is a vendor neutral comprehensive suite of clinically useful AI neuroimaging applications that provide physicians with fully automated, and easy-to-interpret customizable reporting -- facilitating fast and accurate diagnostic and treatment decisions for stroke, neurodegenerative disease, multiple sclerosis and brain tumor patients.
The Neuro AI platform solution for neurodegenerative disease uses AI-based segmentation that provides an accurate and consistent quantitative evaluation of T1-weighted MRI brain scan. The solution offers an automated report that allows users to view a comparison over time, enabling measurements that were impossible to obtain within the time constraints of the clinical workflow using a manual approach.
The Neuro AI platform solution for multiple sclerosis is an automated, reproducible, and accurate tool to detect and quantify white matter lesions on FLAIR MR images. Therefore it delivers an efficient, objective disease activity assessment and determines the best course of treatment. The solution provides data-driven lesion tracking and standardizes reporting for a more efficient workflow and improved communication for both clinicians and patients
Time is brain when it comes to detecting stroke. Using deep learning technologies with robust validation processes to match real-life expectations, the Neuro AI platform’s Stroke Suite detects and prioritizes acute LVO and ICH cases, analyzes CT and MR perfusion, and notifies the radiologist and the care team within their existing systems and workflow.
The Neuro AI platform’s Cerebral 4D Flow is the only solution on the market that leverages Arterys’ 4D flow post-processing technology to visualize and quantify flow measurements in the carotids and intracranial vessels. Cerebral 4D Flow is the only available solution that demonstrates early hemodynamic changes in arteriovenous malformation and monitors blood flow in aneurysms and stenosis. It also provides tools to assess the blood flow of pediatric patients and enables physicians to better plan interventions and stents.
The Neuro-Oncology Suite is part of the Neuro AI platform and it provides tools to non-invasively diagnose and follow up on brain tumors. This solution offers a robust algorithm to distinguish tumors from pseudo-progression with >95% accuracy.
Read some of the articles in prestigious publications that show the Neuro AI Arterys solution addressing imaging advances and research.
Original Research: Cerebrovascular reactivity measurements using simultaneous 15O-water PET and ASL MRI: Impacts of arterial transit time, labeling efficiency, and hematocrit
Original Research: The Effect of Extracranial-to-Intracranial Bypass on Cerebral Vasoreactivity: A 4D Flow MRI Pilot Study
Original Research: Quantification of hemodynamics of cerebral arteriovenous malformations after stereotactic radiosurgery using 4D flow magnetic resonance imaging
Original Research: Simultaneous phase-contrast MRI and PET for noninvasive quantification of cerebral blood flow and reactivity in healthy subjects and patients with cerebrovascular disease
Abstract 167: 4D Flow MRI in Patients With Intracranial Aneurysms: a Comparative Analysis Between Evolving vs. Stable Aneurysms
Neuroradiologists and other radiology subspecialties face unprecedented challenges, with this month's ASNR annual event...
Next month, the Annual Meeting of the American Society of Neuroradiology will be held in tandem with the Symposium...
We have exciting news to share! The Arterys all-in-one neuroradiology Neuro AI platform has launched a new automated...